Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced it will participate in the upcoming DealFlow Discovery Conference, scheduled for January 28–29, 2026, in Atlantic City, N.J. Chief Executive Officer Geordan Pursglove will conduct one-on-one meetings with investors during the event, as the company continues to advance LB-100, its first-in-class inhibitor of protein phosphatase 2A (PP2A), through clinical development.
The announcement highlights Lixte's ongoing efforts to bring novel cancer therapies to market. LB-100 targets a new pathway in cancer biology known as activation lethality, which has shown promise in preclinical studies. According to the company's press release, LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity. The compound has the potential to significantly enhance the effectiveness of chemotherapies and immunotherapies, potentially improving outcomes for patients with various cancers.
Lixte is currently conducting proof-of-concept clinical trials for LB-100 in Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. These studies aim to validate the compound's efficacy and safety in specific patient populations. The company's approach is protected by a comprehensive patent portfolio, covering its pioneering work in the field of activation lethality.
The DealFlow Discovery Conference is a key event for biotechnology and pharmaceutical companies to connect with investors and showcase their latest developments. For Lixte, participation provides an opportunity to discuss the clinical progress of LB-100 and its potential to address unmet medical needs in oncology. The company's presence underscores its commitment to advancing its pipeline and exploring strategic partnerships.
For more information about Lixte Biotechnology and its clinical programs, visit the company's newsroom at http://ibn.fm/LIXT. The full press release regarding the conference participation is available at https://ibn.fm/F1dlA.
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. Its lead compound, LB-100, represents a novel approach to cancer treatment by inhibiting PP2A, an enzyme that plays a role in cell growth and survival. The company's research builds on extensive preclinical data, which can be reviewed at www.lixte.com.
